ALAntoine Legendre

Antoine Legendre

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Antoine Legendre has a total of 180 co-authors. Here are the top co-authors by number of shared publications:

  • Damien Bonnet

    M3C-Necker, hôpital universitaire Necker-enfants malades, AP-HP, 75743 Paris, France; University of Paris Cité, 75006 Paris, France

    8 shared publications
  • Magalie Ladouceur

    Department of Congenital Heart Diseases, Hôpital Marie Lannelongue , 14 Avenue Galilée, 92350 Le Plessis-Robinson

    8 shared publications
  • Diala Khraiche

    M3C-Necker, Unité Médico-Chirurgicale de Cardiologie Congénitale et Pédiatrique, Hôpital Universitaire Necker-Enfants Malades, Paris, Île-de-France, France

    6 shared publications
  • Laurence Iserin

    Unité médico-chirurgicale de cardiologie congénitale adulte, hôpital européen Georges-Pompidou, AP-HP, 75015 Paris, France

    4 shared publications
  • Clément Karsenty

    Pasteur Clinic, Toulouse, France (H.D., C.K., M.R., N.C.).

    3 shared publications
  • Damien Bonnet

    Centre de Référence Malformations Cardiaques Congénitales Complexes (M3C), Hôpital Universitaire Necker-Enfants Malades, AP-HP, 75015 Paris, France; Université de Paris Cité, 75006 Paris, France

    3 shared publications

Latest Publications

  • Cause of death in children with heart disease: a cohort study

    by Neil Derridj, Daphné Madec, Olivier Raisky, Sophie Malekzadeh-Milani, Diala Khraiche, Antoine Legendre, Lucile Houyel, Zahra Belhadjer, Franck Iserin, Mathilde Méot, et al.

    Objective To describe causes of death in children with congenital or acquired heart disease (CAHD) and provide updated mortality data across CAHD groups. Design Prospective observational cohort study (2010–2024). Setting Tertiary paediatric cardiac care centre. Patients All children with CAHD who died during the study period were classified into congenital heart diseases (CHD), cardiomyopathies (CM) and pulmonary hypertension (PH). Main outcome measures Causes of death and demographic characteristics were reported for the entire cohort and by the CAHD group. Results Among 1137 deaths, 244 (21.5%) occurred under compassionate care. The main cohort consisted of 868 (76.3%) children with CHD, 170 (14.9%) with CM and 50 (4.4%) with PH. The median age at death was 2.6 (IQR 14.2) months. Comorbidities and prematurity were observed in 438 (38.6%) and 348 (30.6%) cases, respectively, with no difference among groups. After excluding compassionate care, heart failure was the leading cause of death affecting 359 (40.2%) children, followed by PH crisis in 105 (11.8%) and infections in 101 (11.4%). In the CHD group, severe complexity was predominant in 516 (59.5%) cases, with functionally univentricular heart (172 (33.3%) cases) being the most common subtype. Surgical deaths constituted 625 (72%) cases, with 64 (7.4%) requiring extracorporeal membrane oxygenation (ECMO) and 69 (0.8%) listed for heart transplant. In the CM group, the dilated CM subtype was predominant, accounting for 78 (45.9%) cases, with 12 (7.1%) requiring ECMO. For the PH group, pulmonary arterial hypertension was observed in 34 (68%) cases, with 9 (18%) requiring ECMO. Conclusions Heart failure is the leading cause of death in CAHD, followed by PH, with most deaths occurring within the first year of life, particularly in complex CHD and premature infants.


  • Open Access

    Safety and Efficacy of Dapagliflozin in Patients With Systemic Right Ventricular Dysfunction: DAPA‐SRVTrial

    by Mathieu Albertini, Victor Waldmann, Pauline David, Alexis Barat, Antoine Legendre, Anne‐Solene Chaussade, Laurence Iserin, Magalie Ladouceur

    Background: Heart failure is the leading cause of death in adults with a systemic right ventricle (sRV). While dapagliflozin has proven benefits in patients with acquired heart diseases and heart failure with reduced ejection fraction, its impact remains unknown in patients with an sRV. We aimed to evaluate the safety and efficacy of dapagliflozin in this population. Methods: We conducted a prospective, observational, single‐center study including symptomatic patients (New York Health Association [NYHA] functional class ≥2) with sRV dysfunction despite medical treatment, enrolled from February 2023 to February 2024. Patients were assessed at baseline and 3 and 6 months after dapagliflozin introduction. The primary end point was 6‐Minute Walk Distance (6MWD). Secondary end points included N‐terminal pro‐B‐type natriuretic peptide, quality of life (according to the Kansas City Cardiomyopathy Questionnaire—12‐item version [KCCQ‐12]), NYHA class, systemic and subpulmonary ventricular systolic function, and treatment‐related side effects. Results: A total of 32 patients were included. The mean age of the participants was 48 years (range, 19–79 years), 20 (62%) patients were men, 12 (38%) had congenitally corrected transposition of the great arteries, and 20 (62%) had transposition of the great arteries with atrial switch. At 6 months, 6MWD significantly improved (585 m versus 558 m, P =0.04). Quality of life (91.5 versus 80.5, P P =0.02]; global longitudinal strain: −13.1% versus −11.2% [ P =0.04]) also improved. No significant side effects were observed. Conclusions: This is the first study, to our knowledge, demonstrating the functional benefits and safety of dapagliflozin in symptomatic patients with sRV dysfunction under medical treatment with sacubitril/valsartan. These results support the need for larger randomized trials to further evaluate this therapeutic option in this population.


  • Anatomical insights and management strategies for haemodynamically significant pressure-restrictive perimembranous ventricular septal defects: Findings from the French nationwide FRANCISCO cohort

    by Annabel Sudaka, Jean-Benoit Thambo, Guy Vaksmann, Khaled Hadeed, Ali Houeijeh, Diala Khraiche, Eric Hery, Marie Vincenti, Nicolas Pangaud, Nadir Benbrik, et al.


  • Cyanosis period: A key factor influencing exercise cardiac performance after Fontan procedure

    by Pauline David, Elena Panaioli, Laurence Iserin, Julie Karila-Cohen, Anne-Solène Chaussade, Sophie Malekzadeh-Milani, Fanny Bajolle, Damien Bonnet, Diala Khraiche, Antoine Legendre


  • Rightward imbalanced pulmonary perfusion predicts better exercise stroke volume in children after Fallot repair

    by Elena Panaioli, Diala Khraiche, Neil Derridj, Damien Bonnet, Francesca Raimondi, Antoine Legendre


  • Systematic Electrophysiological Study Prior to Pulmonary Valve Replacement in Tetralogy of Fallot: A Prospective Multicenter Study

    by Victor Waldmann, Francis Bessière, Kevin Gardey, Mohamed Bakloul, Emre Belli, Damien Bonnet, Anne-Solène Chaussade, Sarah Cohen, Hubert Delasnerie, Nabil Dib, et al.

    Background: Ventricular arrhythmias and sudden death are recognized complications in tetralogy of Fallot. Electrophysiological studies (EPS) before pulmonary valve replacement (PVR), the most common reintervention in tetralogy of Fallot, could potentially inform therapy to improve arrhythmic outcomes. Methods: A prospective multicenter study was conducted to systematically assess EPS with programmed ventricular stimulation in patients with tetralogy of Fallot referred for PVR from January 2020 to December 2021. A standardized stimulation protocol was used across all centers. Results: A total of 120 patients were enrolled, mean age 39.2±14.5 years, 53.3% males. Sustained ventricular tachycardia was induced in 27 (22.5%) patients. When identifiable, the critical isthmus most commonly implicated (ie, in 90.0%) was between the ventricular septal defect patch and pulmonary annulus. Factors independently associated with inducible ventricular tachycardia were history of atrial arrhythmia (odds ratio, 8.56 [95% CI, 2.43–34.73]) and pulmonary annulus diameter >26 mm (odds ratio, 5.05 [95% CI, 1.47–21.69]). The EPS led to a substantial change in management in 23 (19.2%) cases: 18 (15.0%) had catheter ablation, 3 (2.5%) surgical cryoablation during PVR, and 9 (7.5%) defibrillator implantation. Repeat EPS 5.1 (4.8–6.2) months after PVR was negative in 8 of 9 (88.9%) patients. No patient experienced a sustained ventricular arrhythmia during 13 (6.1–20.1) months of follow-up. Conclusions: Systematically performing programmed ventricular stimulation in patients with tetralogy of Fallot referred for PVR yields a high rate of inducible ventricular tachycardia and carries the potential to alter management. It remains to be determined whether a standardized treatment approach based on the results of EPS will translate into improved outcomes. Registration: URL: https://clinicaltrials.gov/ct2/show/NCT04205461 ; Unique identifier: NCT04205461


  • Exercise electrocardiogram for risk-based screening of severe residual coronary lesion in children after coronary surgery

    by Johanne Auriau, Zahra Belhadjer, Elena Panaioli, Neil Derridj, Jean-Philippe Jais, Regis Gaudin, Francesca Raimondi, Damien Bonnet, Antoine Legendre


  • Open Access

    FDX2 and ISCU Gene Variations Lead to Rhabdomyolysis With Distinct Severity and Iron Regulation

    by Sebastian Montealegre, Elise Lebigot, Hugo Debruge, Norma Romero, Bénédicte Héron, Pauline Gaignard, Antoine Legendre, Apolline Imbard, Stéphanie Gobin, Emmanuelle Lacène, et al.

    Background and Objectives To determine common clinical and biological traits in 2 individuals with variants in ISCU and FDX2, displaying severe and recurrent rhabdomyolyses and lactic acidosis. Methods We performed a clinical characterization of 2 distinct individuals with biallelic ISCU or FDX2 variants from 2 separate families and a biological characterization with muscle and cells from those patients. Results The individual with FDX2 variants was clinically more affected than the individual with ISCU variants. Affected FDX2 individual fibroblasts and myoblasts showed reduced oxygen consumption rates and mitochondrial complex I and PDHc activities, associated with high levels of blood FGF21. ISCU individual fibroblasts showed no oxidative phosphorylation deficiency and moderate increase of blood FGF21 levels relative to controls. The severity of the FDX2 individual was not due to dysfunctional autophagy. Iron was excessively accumulated in ISCU-deficient skeletal muscle, which was accompanied by a downregulation of IRP1 and mitoferrin2 genes and an upregulation of frataxin (FXN) gene expression. This excessive iron accumulation was absent from FDX2 affected muscle and could not be correlated with variable gene expression in muscle cells. Discussion We conclude that FDX2 and ISCU variants result in a similar muscle phenotype, that differ in severity and skeletal muscle iron accumulation. ISCU and FDX2 are not involved in mitochondrial iron influx contrary to frataxin.


  • Effect of medical treatment on heart failure incidence in patients with a systemic right ventricle

    by Magalie Ladouceur, Teresa Segura de la Cal, Bamba Gaye, Eugenie Valentin, Reaksmei Ly, Laurence Iserin, Antoine Legendre, Elie Mousseaux, Wei Li, Isma Rafiq, et al.

    Background To date, clinical trials have been underpowered to demonstrate a benefit from ACE inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) in preventing systemic right ventricle (sRV) failure and disease progression in patients with transposition of the great arteries (TGA). This observational study aimed to estimate the effect of ACEi and ARB on heart failure (HF) incidence and mortality in a large population of patients with an sRV. Methods Data on all patients with an sRV under active follow-up at two tertiary centres between January 2007 and September 2018 were studied. The effect of ACEi and ARB on the incidence of HF and mortality was estimated using a propensity score weighting approach to control confounding. Results Among the 359 patients with an sRV (32.2 (IQR 26.4–38.3) years, 59.3% male, 66% complete TGA with atrial switch repair and 34% congenitally corrected TGA), 79 (22%) had a moderate to severe sRV dysfunction and 138 (38%) were treated with ACEi or ARB. Fourteen (3.6%) patients died, 8 (2.1%) underwent heart transplantation and 46 (11.8%) had a new HF event over a median follow-up of 7.1 (IQR 4.0–9.4) years. On multivariate Cox analysis with adjustment using propensity score weighting approaches, ACEi or ARBs treatment was not significantly associated with a lower HF incidence or mortality in patients with an sRV. Conclusions Despite significant neurohormonal activation described in patients with an sRV, there is still no evidence of a beneficial effect of ACEi or ARB on morbidity and mortality in this population.


  • Responses to exercise training in patients with heart failure. Analysis by oxygen transport steps

    by Antoine Legendre, Feriel Moatemri, Oksana Kovalska, Maria Balice-Pasquinelli, Jean-Christophe Blanchard, Aurelia Lamar-Tanguy, François Ledru, Pascal Cristofini, Marie-Christine Iliou